SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

This Swedish study is testing whether giving a single immunotherapy drug (nivolumab) or two immunotherapy drugs (nivolumab + ipilimumab) before surgery works better for people with stage III melanoma that can be surgically removed. The goal is to shrink the cancer before surgery and reduce the chance it comes back. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage III melanoma that doctors believe can be fully removed by surgery - Your melanoma is skin-based, on the foot/hand (acral), or from an unknown primary site - You are generally in good health (able to carry out daily activities) - You have not previously received immunotherapy or targeted therapy (BRAF/MEK inhibitors) for melanoma - You are able to use effective contraception if applicable **You may NOT be eligible if...** - Your melanoma is in the eye (uveal/ocular) or from a mucous membrane - Your tumor cannot be completely removed with surgery - You require high-dose steroids or other immune-suppressing medications - You are pregnant or breastfeeding - You have another serious medical condition that could interfere with treatment Talk to your doctor to see if this trial is right for you.